Today’s big question for investors is, “what’s going on with SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) stock? Its price is jumping 0.01 points, trading at $0.15 levels, and is up 8.05% from its previous close of $0.14. The shares seem to have an active trading volume day with a reported 11798250 contracts so far this session. SLS shares had a relatively better volume day versus average trading capacity of 29.88 million shares, but with a 0.23 billion float and a -2.15% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for SLS stock indicates that the average analyst price target is $1.75 per share. This means the stock has a potential increase of 1066.67% from where the SLS share price has been trading recently which is between $0.1276 and $0.1369. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $1.75.
The shorts are climbing into SELLAS Life Sciences Group, Inc. (SLS) stock. The latest set of short interest data was released on 15 August 2019, and the numbers show a rise in short interest in SLS shares. While short interest still represents only 2.02% of SLS’s float, the number of shares shorted have risen by 2456405. The number of shares shorted advanced to 4556965 shares, up from 2100560 shares during the preceding fortnight. With average daily trading volumes at 27116893 shares, days to cover decreased to about 1 days. The most recent news story about the stock that appeared in Yahoo Finance‘s news section was titled “SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2019 Financial Results” and dated August 14, 2019.
During the recent trading session for SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), the company witnessed their stock rise $0.01 over a week and tumble down $-0.02 from the price 20 days ago. When compared to their established 52-week high of $2.46, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 11/09/18. The recent low of $0.1 stood for a -94% since 06/28/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 1.35 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for SELLAS Life Sciences Group, Inc., the two-week RSI stands at 52.04. This figure suggests that SLS stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current SLS readings is similarly very revealing as it has a stochastic reading of 46.26% at this stage. This figure means that SLS share price today is being neutral.
Technical chart claims that SELLAS Life Sciences Group, Inc. (SLS) would settle between $0.14/share to $0.14/share level. However, if the stock price goes below the $0.13 mark, then the market for SELLAS Life Sciences Group, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $0.12 for its downside target.
Analysts at Oppenheimer, assumed coverage of SLS assigning Outperform rating, according to their opinion released on November 01. H.C. Wainwright, analysts launched coverage of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) stock with a Buy recommendation, according to their flash note issued to investors on April 02. Analysts at Maxim Group released an upgrade from Hold to Buy for the stock, in a research note that dated back to March 19.
SLS equity has an average rating of 2, with the figure leaning towards a bullish end. 2 analysts who tracked the company were contacted by Reuters. Amongst them, 1 rated the stock as a hold while the remaining 1 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 1 analysts rated SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Moving on, SLS stock price is currently trading at 0X forward 12-month Consensus EPS estimates, and its P/E ratio is NA while for the average stock in the same group, the multiple is -6.49. SELLAS Life Sciences Group, Inc. current P/B ratio of 2.15 means it is trading at a discount against its industry’s 3.44.